Da hast du absolut recht, man findet immer noch beide Zahlen auf der Biontech Homepage, scheint niemand aufgefallen zu sein:
100 Mio: biontech.de/covid-19
"In case the safety and efficacy study is successful, BioNTech and Pfizer plan to seek regulatory review as early as October 2020 and, if regulatory authorization or approval is obtained, expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021."
50 Mio: investors.biontech.de/news-releases/...rization-world-vaccine
"Based on current projections, Pfizer’s and BioNTech’s combined manufacturing network has the potential to supply globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021 (subject to manufacturing capacity and regulatory approval or authorization)."
Ich denke, man muss Biontech zugute halten, dass alles, was nun passiert, für die Firma komplett neu ist. Man darf gerade im PR & Kommunikationsbereich noch nicht den Level an Professionalität erwarten, den andere bereits haben.